Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals Inc (NQ: PIRS )

16.77 UNCHANGED
Streaming Delayed Price Updated: 3:53 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pieris Pharmaceuticals Inc

< Previous 1 2 Next >
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
From Kahn Swick & Foti, LLC
Via Business Wire
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics
Via GlobeNewswire
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment... 
From Palvella Therapeutics
Via GlobeNewswire
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
Via ACCESSWIRE
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
Via ACCESSWIRE
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, ENV, PIRS, BALY on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
From Kahn Swick & Foti, LLC
Via Business Wire
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Via ACCESSWIRE
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Via ACCESSWIRE
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Via ACCESSWIRE
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
Via ACCESSWIRE
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
Via ACCESSWIRE
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
Via ACCESSWIRE
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Via ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
Via ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.